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Are Immune Modulating Single 
Nucleotide Polymorphisms 
Associated with Necrotizing 
Enterocolitis?
Ashanti L. Franklin1, Mariam Said2, Clint D. Cappiello1, Heather Gordish-Dressman3, 
Zohreh Tatari-Calderone4, Stanislav Vukmanovic4, Khodayar Rais-Bahrami2,  
Naomi L. C. Luban5, Joseph M. Devaney6 & Anthony D. Sandler7
Necrotizing enterocolitis (NEC) is a devastating gastrointestinal emergency. The purpose of this study 
is to determine if functional single nucleotide polymorphisms (SNPs) in immune-modulating genes 
pre-dispose infants to NEC. After Institutional Review Board approval and parental consent, buccal 
swabs were collected for DNA extraction. TaqMan allelic discrimination assays and BglII endonuclease 
digestion were used to genotype specific inflammatory cytokines and TRIM21. Statistical analysis was 
completed using logistic regression. 184 neonates were analyzed in the study. Caucasian neonates with 
IL-6 (rs1800795) were over 6 times more likely to have NEC (p = 0.013; OR = 6.61, 95% CI 1.48–29.39), 
and over 7 times more likely to have Stage III disease (p = 0.011; OR = 7.13, (95% CI 1.56–32.52). 
Neonates with TGFβ-1 (rs2241712) had a decreased incidence of NEC-related perforation (p = 0.044; 
OR = 0.28, 95% CI: 0.08–0.97) and an increased incidence of mortality (p = 0.049; OR = 2.99, 95% 
CI: 1.01 – 8.86). TRIM21 (rs660) was associated with NEC-related intestinal perforation (p = 0.038; 
OR = 4.65, 95% CI 1.09–19.78). In premature Caucasian neonates, the functional SNP IL-6 (rs1800795) 
is associated with both the development and increased severity of NEC. TRIM21 (rs660) and TGFβ-1 
(rs2241712) were associated with NEC- related perforation in all neonates in the cohort. These findings 
suggest a possible genetic role in the development of NEC.
Necrotizing enterocolitis (NEC) is a leading cause of morbidity and mortality among preterm neonates1,2. Its 
prevalence has increased over the last 30 years as advances in neonatal critical care have led to improved survival of 
more preterm neonates. In fact, a recent study looking at mortality among extremely premature neonates between 
2000–2011, noted that although overall mortality among this population has declined, deaths related to NEC have 
increased3. There is an overall mortality rate of 20–30% in infants with NEC and approaches 100% in neonates with 
pan-intestinal disease (NEC totalis)4. The onset of NEC is variable, and is inversely proportional to gestational age5. 
Signs and symptoms of the disease are often non-specific and require a high index of suspicion. The diagnosis of 
NEC is made using specific criteria as classified by the Modified Bell Staging (Table 1)6,7.
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In the preterm infant, the gastrointestinal host defense is impaired, thereby increasing the risk of intestinal 
injury8. This inadequate host response allows for bacterial translocation and may lead to activation of an inflamma-
tory cascade, resulting in global inflammatory effects and localized gastrointestinal inflammation9. Subsequently, 
several inflammatory mediators are released through activation of human toll like receptors (TLRs)2,4,10. Multiple 
inflammatory mediators are implicated in the pathogenesis of NEC11–14. Additionally, several studies have demon-
strated that infants with NEC have elevated serum levels of inflammatory cytokines15–17. This finding however has 
no bearing on etiology, as it may simply be a pathologic response to the inflammatory process already underway.
Few studies have interrogated the role of genetics in the pathogenesis of NEC18–20. In an attempt to study 
whether an exaggerated inflammatory response has a causal relationship to developing NEC, we sought to identify 
genetic markers of the disease. In this study, we examined select single nucleotide polymorphisms (SNPs) among 
various inflammatory genes. Genes of interest were selected based on known associations between inflammatory 
mediators and NEC12–14,21. SNPs are naturally occurring single base pair changes in the genome. SNPs can alter 
the translation of their related proteins, altering function and disease processes. SNPs in TNFα and IL-6 are 
associated with altered levels of cytokines in serum, worsened outcomes in trauma patients, and various other 
pathologies22–25. We hypothesize that SNPs in genes encoding various inflammatory modulators may be associated 
with the exuberant gastrointestinal inflammation observed in NEC.
Methods
Patient Selection. This study was approved by the Institutional Review Board (IRB) at Children’s National 
Health System (Washington, DC, USA). All experiments were conducted according to institutional and IRB 
guidelines and regulations. Parental and/or guardian consent was obtained in accordance with our institutional 
policies. This was a prospective cohort study, in which premature neonates were recruited from the Neonatal 
Intensive Care Unit (NICU) at Children’s National Health System. Neonates < 32 weeks gestation and any infant 
with the diagnosis of NEC (>Bell stage II) regardless of gestational age were included in the study. Controls were 
infants < 32 weeks without the diagnosis of NEC (>Bell stage II). Neonates with congenital heart disease (except 
patent ductus arteriosus), major congenital or chromosomal disorders, and/or inborn errors of metabolism were 
excluded. Infants with complex congenital heart disease (CCHD) were excluded from the study to allow us to more 
clearly interrogate the role of genetics in NEC. Infants with CCHD, particularly those with left-sided obstructive 
cardiac lesions, have an increased risk of developing NEC due to potential intestinal hypoperfusion, thought to 
result from episodes of inadequate cardiac output, shock and diastolic flow reversal in the abdominal aorta26.
Sample Collection and Preparation. Cytological brushes were used to swab the buccal mucosa and obtain 
neonatal DNA using methodology previously validated by our group27. Enrolled subjects were nil per os (NPO) 
at the time of buccal swab collection. DNA was extracted from buccal swab specimens using Qiagen Buccal Cell 
Kit (Qiagen Sciences, Germantown, MD). The buccal cell extraction kit was modified for a cell lysate volume of 
900μ l27. After cell lysis, genomic DNA was extracted with 5 μ l proteinase k and isopropanol/ethanol precipitation.
Genotyping of TRIM-21. PCR amplification–AccuPrime Taq DNA polymerase system (Invitrogen – Grand 
Island, NY). 100–200 ng of genomic DNA was amplified using the provided protocol for a 50 uL reaction. The 
PCR cycle was optimized for our primers− 94 °C × 2 min, 94 °C × 30 sec, 58 °C × 30 sec, 68 °C × 30 sec for 35 cycles, 
68 °C × 6 min, 10 °C∞. Forward primer sequence: 5′ –CTG TAC ATC CAC AGT GAG C–3′ . Reverse primer 
sequence: 5′ –CAT CCC TTG TCA GAT GGA TAG–3′ . A 3% agarose gel with NuSieve 3:1 was used to assess the 
presence of PCR products.
Allelic discrimination of TRIM21 with BglII (New England BioLabs – Ipswich, MA) digestion. 5 uL of PCR product 
was used in a 50 uL reaction for restriction enzyme digestion with BglII28,29. Allelic discrimination was based on 
resultant banding patterns of digested fragments using gel electrophoresis as previously described28,29. Undigested 
PCR products produce 420 bp band (Fig. 1a). The rs660 SNP is a T → C polymorphism that alters the binding site 
of BglII. The resulting banding patterns correspond to the following genotypes: TT (420 bp band), TC (420 bp, 
255 bp, 165 bp) and CC (255 bp, 165 bp) (Fig. 1b).
Genotyping of inflammatory cytokine genes. Genotyping of SNPs from the following inflammatory 
cytokines IL-1B (rs16944), IL-6 (rs1800795), IL-12 (rs3212227), NOS3 (rs1800779), PXR (rs6785049), TGFβ -1 
Modified 
Bell’s Staging Clinical Findings Radiographical Findings Gastrointestinal Findings
Stage I Apnea, bradycardia, and temperature instability Normal gas pattern or mild ileus Mild abdominal distention, stool occult blood, gastric residuals
Stage IIA Apnea, bradycardia, and temperature instability Ileus with dilated bowel loops and focal pneumatosis
Moderate abdominal distention, 
hematochezia, absent bowel sounds
Stage IIB Metabolic acidosis and thrombocytopenia Widespread pneumatosis, portal venous gas, ascites Abdominal tenderness and edema
Stage IIIA Mixed acidosis, coagulopathy, hypotension, oliguria
Moderate to severely dilated bowel 
loops, ascites, no free air
Abdominal wall edema, erythema, 
and induration
Stage IIIB Shock, worsening vital signs and laboratory values Pneumoperitoneum Bowel perforation
Table 1.  Modified Bell’s Staging Criteria (Kliegman et al.12).
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(rs2241712), TLR4 (rs4986790), and TNFα (rs1800629) were completed utilizing TaqMan® Gene Expression 
system (Life Technologies, Grand Island, NY). Assays for IL-1B (C___1839943_10), IL-6 (C___1839697_20), 
IL-12 (C___2084293_10), NOS3 (C___7599687_1_), PXR (C__29280426_10), TGFβ -1 (C__15873873_10), 
TLR4 (C__11722238_20), and TNFα (C___7514879_10) were purchased from Life Technologies. Genotypes 
were obtained using a TaqMan® allelic discrimination assay that employs the 5′ nuclease activity of Taq polymerase 
to detect a fluorescent reporter signal generated during PCR reactions. The PCR reactions contained 20 ng/μ l of 
DNA, 900 nM primers, 200 nM probes, and TaqMan® Universal PCR Master Mix, No AmpErase® UNG (Applied 
Biosystems, Foster City, CA) in a final volume of 8 μ l.
Statistics. Statistical analysis was completed using a dominant model, comparing wild-type homozygous to 
both heterozygous and homozygous rare allele groups combined. This assumes that carrying at least one copy 
of the variant allele confers increased or decreased risk of disease30,31. Primary outcome measures included the 
presence of NEC, severity of disease (Bell’s stage III, NEC totalis), NEC-related bowel perforation, and mortality. 
Hardy-Weinberg equilibrium (HWE) was determined using a χ 2 test to compare the observed genotype frequen-
cies to those expected under Hardy-Weinberg equilibrium (HWE). Comparisons of genotype frequencies and 
outcomes between Blacks and Caucasians were performed using χ 2 tests. Fisher’s exact test was used to perform 
crude comparisons between outcomes in Blacks versus Caucasians. Logistic regression or exact logistic regression 
was used depending on the number of subjects available for analysis. Ordinal logistic regression was utilized to 
compare severity of disease. Significance level was set at p < 0.05 and Stata V13 was (College Station, TX) used 
for all statistical analysis.
The analysis was performed using a two-stage analysis. Initially, associations between each outcome and each 
SNP were evaluated in the entire patient cohort with adjustment for race, ethnicity, gestational age, and gender. Only 
those outcomes/SNP pairs that showed either a statistically significant association (p < 0.05) or some evidence of a 
relationship (p < 0.15) were further investigated in racial/ethnic specific cohorts. All additional analyses included 
covariates for gestational age and gender.
Results
Two-hundred and five patients were enrolled in the study (Fig. 2). Twenty-one infants were excluded from analysis. 
One infant was found to have congenital heart disease (Tetralogy of Fallot). Two patients, initially diagnosed with 
NEC according to clinical presentation and radiographic evidence of pneumatosis, were found to have intestinal 
volvulus intraoperatively. Eighteen infants had a diagnosis of spontaneous intestinal perforation (SIP). SIP was 
distinguished from NEC based on radiographic imaging, clinical presentation, surgical findings, and medication 
history. Despite distinct differences between the two diseases, infants with SIP were excluded to not confound 
the data analysis.
Figure 1. PCR Amplification and BglII endonuclease digestion; (a) PCR amplification of TRIM21 rs660 
with a product at 420 bp. (b) Rs660 there is a nucleotide alteration from T to C that will alter the site of BglII 
endonuclease digestion with resultant products at 255 and 165 bp.
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The remaining 184 infants had a mean gestational age of 27.3 ± 3.3 weeks (22–40), and a mean birth weight 
of 1.02 ± 0.52. 101 (54.9%) enrolled subjects were male and 83 (45.1) female. There were 121 (65.8%) Black and 
59 (32.1%) Caucasian subjects in this study (Table 2). Most patients were Non-Hispanic (81.4%). Assignation of 
race and ethnicity were determined by parental self-reporting. There were 118 controls and 66 patients with NEC 
(>Bell stage II). Of those neonates with NEC, 42 had surgical NEC, including bedside peritoneal drain placement 
and/or exploratory laparotomy (Table 3). 14 infants with Stage III disease were diagnosed with NEC totalis. The 
overall mortality rate was approximately 12% (n = 23), with over 70% of deaths in this cohort attributed to NEC 
(n = 17). In our study, Blacks and Caucasians of both Hispanic and Non-Hispanic ethnicity showed no significant 
differences in any of the measured outcomes (Table 4). There were substantial differences in allele frequencies 
between Caucasians and Blacks (supplemental Table 1), therefore, subsequent analyses were completed in Black 
and Caucasian subjects as individual cohorts. Individual analyses in the remaining racial categories (Asian or 
Other) were unable to be completed due to inadequate sample size. In the Black population, IL-12 (rs3212227) 
and PXR (rs6785049) were not in HWE. In Caucasians, IL1B (rs16944) and TLR4 (rs4986790) were not in HWE.
Initial analyses in the total cohort of patients showed some evidence of a relationship between the following 
outcomes and SNPs: IL-6 (rs1800795) with NEC and severity of disease, TGFβ -1 (rs2241712) with overall mor-
tality and NEC perforation, and TRIM21 (rs660) with NEC perforation (Table 5). These associations were further 
analyzed in Blacks and Caucasians as separate cohorts.
In the total cohort, the G allele of TGFβ -1 (rs2241712) was associated with a significantly decreased incidence 
of NEC-related perforation (p = 0.044; OR = 0.28, 95% CI: 0.08–0.97) and a significantly increased incidence of 
overall mortality (p = 0.049; OR = 2.99, 95% CI: 1.01 – 8.86). These associations were not statistically significant 
in either of the race specific cohorts. In all subjects with NEC, TRIM21 (rs660) was associated with NEC-related 
Figure 2. Study Cohort. 
Variable Total (n = 184) Control (n = 118) NEC (n = 66) p-value
Male sex, n (%) 101 (54.9) 61 (51.7) 40 (60.6) 0.24
GA (weeks), mean ± SD 27.3 ± 3.3 27.1 ± 2.74 27.6 ± 4.14 0.33
Birth Weight (kg), 
mean ± SD 1.02 ± 0.52 0.99 ± 0.37 1.07 ± 0.51 0.22
Race
 Black, n (%) 121 (65.8) 75 (63.6) 46 (69.7) 0.42
 Caucasian, n (%) 59 (32.1) 41 (34.8) 18 (27.3) 0.33
 Asian, n (%) 2 (1.1) 0 (0.0) 2 (3.0) 0.12
 Other, n (%) 2 (1.1) 2 (1.7) 0 (0.0) 0.53
Ethnicity
 Hispanic, n (%) 34 (18.5) 23 (12.5) 11 (6) 0.70
Mortality 23 (12.5) 6 (5.1) 17 (25.7) < 0.001
Table 2.  Demographics.
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intestinal perforation (p = 0.038; OR = 4.65, 95% CI 1.09–19.78). When evaluating TRIM21 in race specific cohorts, 
no association between NEC-related intestinal perforation and TRIM21 was found. In the total cohort, the C allele 
of IL-6 (rs1800795) trended toward an increased prevalence of NEC (p = 0.11; OR = 1.74, 95% CI: 0.88–3.42), as 
well as an increased severity of NEC (p = 0.054; OR = 2.06, 95% CI: 0.98–4.13). Analysis of Black neonates with 
IL-6 (rs1800795) showed no association between the incidence of NEC or severity of disease. Caucasian neo-
nates with the C allele of IL-6 (rs1800795) were over 6 times more likely to have NEC than those with no C allele 
(p = 0.013; OR = 6.61, 95% CI 1.48–29.39) (Table 6). Caucasian neonates with the C allele of IL-6 (rs1800795) 
were also significantly more likely to have stage III than those without the C allele (p = 0.011; OR = 7.13, 95% CI 
1.56–32.52) (Table 6).
Variable NEC cases (n = 66)
Surgical NEC 42 (63.6)
NEC Perforation 25 (37.9)
NEC-related Mortality 17 (25.8)
NEC Totalis 14 (21.2)
Black 46 (69.7)
 Stage II 11 (23.9)
 Stage III 35 (76)
  Totalis 12 (34.3)*
Caucasian 18 (27.3)
 Stage II 9 (50)
 Stage III 9 (50)
  Totalis 2 (22.2)*
Asian 2 (3)
 Stage II 2 (100)
Table 3.  NEC Demographics. *indicates percentage of NEC stage III patients with given characteristic.
Variable Black (n = 121) Caucasian (n = 59) p-value
NEC, any stage, n (%) 46 (38) 18 (30.5) 0.41
NEC Stage III, n (%) 35 (28.9) 7 (11.9) 0.014
NEC Totalis, n (%) 12 (9.9) 2 (3.3) 0.15
NEC Perforation, n (%) 20 (16.5) 6 (10.2) 0.37
Overall Mortality, n (%) 18 (14.9) 4 (6.8) 0.15
NEC Mortality, n (%) 14 (11.6) 3 (5) 0.19
Table 4.  Comparison of outcomes between Blacks and Caucasians.
SNP Outcome Genotype
Outcome
OR p-value 95% CINo Yes
IL-6 (rs1800795) NEC
GG 93 25 1.00
CG/CC 40 40 1.74 0.11 0.88– 3.42
IL-6 (rs1800795) Overall mortality
GG 109 13 1.00
CG/CC 50 9 2.54 0.08 0.90–7.23
TGFβ -1 (rs2241712) Overall mortality
AA 66 5 1.00
AG/GG 92 18 2.99 0.049 1.01–8.86
TGFβ -1 (rs2241712) NEC perforation
AA 12 12 1.00
AG/GG 28 13 0.28 0.044 0.08–0.97
TRIM21 (rs660) NEC perforation
TT 16 4 1.00
CT/CC 16 15 4.64 0.038 1.09–19.78
SNP Outcome Genotype
Severity level
OR p-value 95% CI0 2 3
IL-6 (rs1800795) NEC severity
GG 83 14 26 1.00
CG/CC 34 8 17 2.06 0.054 0.98–4.13
Table 5.  Potential associations seen in the entire cohort.
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In order to determine whether having multiple SNPs increased the risk of developing disease, a multi-SNP 
analysis was performed, with no significant results. A genetic risk score model to include IL-6, TRIM21 and TGFB1 
was used, and did not find any evidence that the combined SNPs were better predictors of NEC (Table 7). This 
lack of a clear association may be in part due to the low numbers of individuals having none of the “risk” alleles 
for the SNPs, a limiting factor in this study.
Discussion
This is one of the largest studies from the United States evaluating functional SNPs in immune modulating genes 
among neonates. While the exact pathogenesis of NEC remains unclear, it is widely accepted that an exuberant 
gastrointestinal inflammatory state accompanies this disease. In our study, over 30% of enrolled subjects had 
NEC. Of those with NEC, nearly 70% had surgical NEC and 21% had NEC totalis. The incidence of NEC in our 
study population is much greater than the national incidence, but similar to that reported from other freestanding 
children’s hospitals32. The increased prevalence and severity of disease in our study population is likely attributed 
to the fact that our NICU serves solely as a referral site for critically ill neonates in the region. In addition, our 
cohort is comprised largely of Blacks, (reflective of our overall NICU racial demographics), and may be related to 
the higher prevalence of NEC33. Contrary to the literature33, there was no significant difference in the incidence 
of NEC and severity of disease between race in our study population.
Multiple studies have shown that pro-inflammatory cytokines are increased in the serum and tissue of patients 
with NEC15–17,34. Additionally, several studies have demonstrated that neonates with NEC had a significantly higher 
elevation of serum inflammatory cytokines than infants with other gastrointestinal diseases33,35,36. Functional SNPs 
in inflammatory cytokines may be associated with an altered basal level expression of the cytokines in serum and 
disease37–39. This observation supports our hypothesis that functional SNPs that alter cytokine serum levels may 
predispose neonates to the excessive inflammation associated with NEC.
IL-6 is a proinflammatory cytokine that functions as a mediator of the acute phase response and fever. IL-6 
(rs1800795) is located on chromosome 7 in the 5′ flanking promoter region and has a single nucleotide base sub-
stitution from a G to C allele at position 17425,40. The C allele is more common in Caucasians than in Blacks41 and 
is associated with an increased odds of developing NEC and having more severe disease. IL-6-174C is associated 
with an alteration in the promoter region that increases transcription of IL-6, which may predispose premature 
Caucasian infants to NEC. In the literature, there is conflicting evidence on the role of IL-6 expression in IL-6-
174 genotypes. Kilpinen et al.40, found that neonatal monocytes stimulated with lipopolysaccharide (LPS) had 
higher IL-6 expression in neonates with IL-6-174C when compared to those with the G allele. Similarly, plasma 
expression of IL-6 was higher in neonates with IL-6-174C. Reiman et al.24, found that IL-6-174GG was associated 
with chorioamnionitis and IL-6-174CC was associated with neonatal sepsis. Reiman et al 24 did not find an asso-
ciation between IL-6- 174 and NEC, however this was likely due to very small sample size. Conversely, Fishman et 
al.25 found that the IL-6-174CC was associated with lower levels of IL-6 in the plasma of adults and may confer a 
protective benefit against juvenile chronic arthritis. Although we do not know the exact mechanism of IL-6-174C 
association with NEC in Caucasian neonates it is plausible that this SNP regulates IL-6 response to antigens in 
SNP Outcome Genotype
Outcome
OR p-value 95% CINo Yes
IL-6 (rs1800795) NEC
GG 24 3 1.00
CG/CC 16 15 6.61 0.013 1.48–29.39
SNP Outcome Genotype
Severity
OR p-value 95% CI0 2 3
IL-6 (rs1800795) NEC severity
GG 24 2 1 1.00
CG/CC 16 7 8 7.13 0.011 1.56–32.52
Table 6.  Association between IL6 and NEC in Hispanic and Non-Hispanic Caucasians.
Outcome Race/ethnicity
Genotype risk 
score
Outcome
OR p-vzalue 95% CI
P-value for trend 
over all risk 
scoresNo Yes
NEC African-Americans
0 17 11 1.00
0.56
1 37 22 0.94 0.90 0.37–2.41
2 16 10 0.98 0.97 0.32–2.96
3 5 1 0.33 0.34 0.03–3.28
NEC Caucasians
0 7 1 1.00
0.09
1 21 7 1.77 0.63 0.17–18.62
2 11 7 2.72 0.42 0.23–31.38
3 2 3 9.97 0.12 0.53–185.69
Table 7.  Combined risk score with risk alleles for IL-6, TRIM21 and TGFβ-1.
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naïve neonatal cells leading to exuberant inflammatory response seen in infants with NEC40. Caucasian neonates 
with the C allele of IL-6 (rs1800795) were over 6 times more likely to have NEC. In addition, Caucasian infants 
with IL-6-174C were over 7 times more likely to have Stage III disease. This supports a hypothesis that an altered 
inflammatory state may be involved in the pathogenesis of NEC. Furthermore, our findings elucidate a possible 
genetic basis for the predisposition to NEC.
Our study revealed that infants with TRIM21 (rs660) were over 4 times more likely to have a NEC-related 
perforation. TRIM21 is a tripartite motif protein that is located on chromosome 11p15.5 in the non-coding region 
of the gene and leads to a single base alteration from a C to T allele28,29,42. Depending on the context, TRIM21 
can have proinflammatory or anti-inflammatory actions43. TRIM21 can also serve as an intracellular receptor for 
antigen-antibody complexes internalized via cell surface receptors that infectious agents use to enter the cells. This 
intracellular interaction results in activation of intracellular immune pathways44. This activates the production 
of pro-inflammatory cytokines, which promote resistance to viruses and intracellular bacteria45. Conversely, in 
TRIM21 knock-out mice, TRIM21 functioned as a downregulator of NFκ B and interferon signaling, highlighting 
its function as an anti-inflammatory protein46,47. A key question for understanding the potential role of TRIM21 
in NEC is whether immune complexes formed by unknown antigens are involved in the pathogenesis of NEC. 
In either case, based on earlier studies by Tatari-Calderone et al.28 and Yoshimi et al.42 we predict that the rs660C 
allele is associated with lower levels of TRIM21. Therefore based on these and other studies28,42,46,47 it is possible 
that a decrease in TRIM21 as a result of the rs660C allele leads to an unregulated gastrointestinal pro-inflammatory 
response in neonates with NEC leading to the morbidity of NEC-related perforation.
TGFβ -1 (rs2241712) had a protective effect against NEC-related perforation in neonates with NEC, yet showed 
an increased incidence of overall mortality among the entire cohort. TGFβ -1 plays a role in immune modulation, 
anti-inflammation, and cell growth and differentiation. TGFβ -1 (rs2241712) is located on chromosome 19q in the 
3′ UTR promoter region and leads to a single base change of G to A48. There is no data in the literature regarding 
the function of TGFβ -1 (rs2241712) or its effect on altering basal levels of TGFβ -1 in serum. It is thus not possible 
to explain the paradoxical effect of protection against intestinal perforation, yet increased overall mortality. More 
studies are needed to evaluate these seemingly paradoxical effects in NEC.
There are several limitations in this study. Although this study is one of the largest prospective cohort studies 
in the United States evaluating the genetic basis for NEC, our sample size is relatively small. Several outcome 
measures could not be adequately tested in the race specific cohorts due to an inadequate sample size, therefore the 
study may not be powered to detect a definitive association between SNPs in inflammatory cytokines and TRIM 
21 and the diagnosis of NEC. The confidence intervals in our study were often wide in part due to the relatively 
small sample size. TGFβ -1 (rs2241712) and TRIM21 (rs660) were associated with NEC-related perforation in all 
subjects after adjusting for race and ethnicity, however this association was either not present or did not have an 
adequate sample size to test within individual racial groups making conclusions difficult. The large number of 
patients transferred for surgical management of NEC may have led to a selection bias. Additionally, to determine 
if there is an actual “cause and effect” relationship, inflammatory cytokines should be measured in plasma before 
and after the clinical presentation of NEC.
Conclusion
Caucasian neonates with IL-6-174-C were over 6 times more likely to have NEC, and over 7 times more likely 
develop more severe disease. This study is a novel, large, and ongoing prospective cohort study evaluating the 
genetic predisposition to NEC. In addition, this study generates hypotheses for further genetic testing in neonates 
to determine predisposition to various neonatal diseases. Furthermore, association of multiple SNPs and NEC 
may allow for the development of a laboratory genetic test that could predict the risk/probability of premature 
neonates developing NEC. Identifying such an association would allow for preventative medical measures in these 
infants and provide insights into the pathogenesis of this disease, establishing the foundation for future therapies.
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